Dasan Pharma., a pharmaceutical CDMO (contract development and manufacturing organization) specialist, has secured $8.8 million (13 billion KRW) in pre-IPO investment. The funding round was led by major Korean investment banks KB Securities and NH Investment & Securities. With this strategic capital injection ahead of its listing, Dasan Pharma expects to accelerate its corporate value enhancement and global market expansion.

Dasan Pharma has built comprehensive development and production capabilities spanning from active pharmaceutical ingredients to finished drugs. The company maintains a solid market share in chronic disease treatments, particularly hypertension medications, based on high-tech formulation technologies including drug delivery systems (DDS), Multi-Stra, proprietary polymer material technology, and fluidized bed coating technology.

Recently, the company has been expanding its research scope beyond its traditional strength in oral formulations to transdermal and injectable formulations, demonstrating its technical capabilities.

Dasan Pharma plans to concentrate the secured funds on expanding production facilities, R&D for new products, and targeting the global CDMO market. The company’s strategy includes responding swiftly to increasing domestic and international orders through production infrastructure expansion and diversifying its portfolio by developing next-generation new formulations.

“This pre-IPO investment is an important milestone that strengthens our financial structure before listing while receiving market recognition of Dasan Pharma’s growth potential,” said Hyung-seon Ryu, CEO of Dasan Pharma. “Through aggressive investment, we will maximize competitiveness in the global CMO market and successfully complete our KOSDAQ listing in close cooperation with our lead underwriter, NH Investment & Securities.”